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1. Introduction 
The first monoclonal antibody (Mab), developed against kidney transplant rejection, was 
accepted by the FDA in 1986 [1]. Today, Mabs are leading the biotherapeutics market as 28 
have been approved in Europe and the USA, and hundreds are in clinical trials [2-4]. Most of 
them are of IgG1 subtype, developed for cancer and immune disease treatments. Mabs clinical 
efficacy not only relies on specific target binding provided by their variable region, but also on 
their ability to trigger defense mechanisms such as antibody-dependent cellular cytotoxicity 
(ADCC) and complement dependent cytotoxicity (CDC). These effector functions are 
mediated by the interaction between the antibody Fc fragment and the Fcγ-receptors 
expressed on immune cell surfaces or the molecules of the complement involved in ADCC and 
CDC respectively. In the last decade, these interactions were found to be highly dependent on 
on the presence and structure of the N-glycan linked to the Fc fragment [5, 6]. 
Fc fragments possess two conserved N-glycosylation sites on asparagine 297 in the CH2 
domain of each heavy chain. Mabs produced in mammalian cells possess a wide variety of 
glycoforms, as the attached glycans are modified to different extents with core-fucosylation, 
bisecting N-acetylglucosamine addition, galactosylation and sialylation. The glycan 
composition is crucial, as the presence or absence of a single monosaccharide residue can 
remarkably affect the affinity of the Mab for the different Fcγ-receptors. Among the variety 
of monosaccharides present on Fc glycans, terminal sialic acids are particularly interesting, 
as their role in Mab functions is both positive and negative. Sialylation of the Fc glycan 
dramatically decreases Mab affinity for the canonical Fc receptors, thereby inhibiting ADCC. 
However, recent studies on the anti-inflammatory properties of intravenous 
immunoglobulins (IVIg) suggest that this biological activity could be conferred by the 
presence of α2,6-sialic acid residues on the Fc glycans. Although this hypothesis is still 
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controversial, the study has raised a new interest in α2,6-sialylated IgGs. While glycosylation 
of therapeutic Mabs significantly impact their biological activity, the production of Mabs with 
a specific homogenous glycoform profile is in general beyond the reach of manufacturing 
bioprocesses. In this chapter, we describe and compare two large-scale transient expression 
platforms using chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293) 
cells for the production of highly sialylated monoclonal antibodies. 
2. IgG N-glycans and their interactions with the Fc 
Glycosylation is a complex process that involves several glycosyltransferases and 
glycosidases. Most glycosylation sites are located on the glycoprotein surface, whereas IgGs’ 
N-glycans are embedded within the Fc fragment. This particular location restricts the access 
of glycosyltransferases to their substrates, thereby reducing glycan complexity. 
Subsequently, while tri- and tetra-antennary glycans can be found on many glycoproteins 
such as EPO or IgG Fab fragments, Fc N-glycans are of the complex biantennary type [7] 
that consists of a heptasaccharide core structure comprising four N-acetylgalactosamines 
(GlcNAc) and three mannoses (Figure 1). The α1,3 and α1,6 arms can be further elongated 
with galactose and sialic acid. Fucose and bisecting-GlcNAc can be found on the core 
GlcNAc and on the central mannose respectively. This glycan is rarely fully processed; the 
predominant glycoform found on antibodies produced in CHO and 293 cell cultures is the 
fucosylated core-structure. 
 
Figure 1. IgG1 glycan bi-antennary complex structure. Glycan interactions with CH2 amino acids. Sia: 
sialic acid; Gal: galactose; GlcNAc: N-acetylglucosamine; Man: mannose; Fuc: fucose. 
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The CH2 amino acid sequence around Asn297 is very well conserved amongst IgG subtypes. 
Several amino acids have been shown to interact with the glycan located on the same heavy 
chain (HC), whereas no interaction is likely to happen with the other heavy chain. Amino 
acid-glycan interactions determine the glycan position within the Fc pocket and its 
availability for glycosyltransferases. The galactose (Gal) on the α1,6 arm is the main residue 
retaining the glycan on the protein surface [6, 8, 9] by generating H-bonds with Lys246 and 
Thr260 [6]. In IgG1 and IgG4 subtypes, galactosylation occurs preferentially on α1,6 branch 
[8, 10]. The inner saccharides have less interaction with the protein. The first and second 
GlcNAc residues generate H-bonds with Asp265 and Arg301 respectively [6]. They also 
form a CH/π interaction with the non-polar moieties of Val264 and Phe241 [6]. Similarly, the 
GlcNAc residue on the α1,6 branch also forms a CH/π interaction with Phe243 [11]. In 
contrast to galactosylation, sialylation preferentially occurs on the α1,3 arm. It has been 
suggested that the galactose on the α1,6 arm may limit further elongation by maintaining 
the branch close to the CH2 protein surface [8]. However, even if steric hindrance may play a 
role, branch α2,6-sialylation specificity was shown to be a consequence of ST6Gal-I α1,3 arm 
preference [12], a phenomenon that is protein independent. The presence or absence of a 
sugar residue on the Fc glycan thus affects the conformation of the Fc, thereby affecting the 
Fc-mediated effector functions. These effects are summarized in Table 1. 
 
 
Mab-FcγR
Affinity 
Mab-C1q
Affinity 
Impacted effector function Reference 
b-GlcNAc +  ADCC Umaña 1999 
Fucose -  ADCC Shields 2002, Shinkawa 2003 
Galactose  + CDC Hodoniczky 2005 
Sialic acid -  ADCC Scallon 2007 
Table 1. Impact of the presence of extra-core monosaccharides on IgG ADCC and CDC effector 
functions. 
3. Sialic acids in Fc N-glycans 
The half-life of a number of glycoproteins can be enhanced by sialylation, as sialic acid 
acts as a cap that hides the penultimate galactose residue recognized by the hepatic 
asialoglycoprotein receptor (ASGPR, or Ashwell-Morell receptor) [13]. Sialic acid can be 
linked to the galactose either with α2,3 or α2,6 linkage. Recent studies showed that α2,3 
sialylation provides a better protection to the protein than α2,6 sialylation, as ASGPR 
recognizes Siaα2,6Gal and Siaα2,6GalNAc moieties in addition to the well-known Gal and 
GalNAc residues [14, 15]. However, Fc-glycans have no apparent impact on IgG half-life 
[16]. The benefits of IgG sialylation on in vivo properties of IgGs are still to be understood. 
Recent studies suggest that sialylation provides anti-inflammatory properties to IgGs. It 
was observed that IVIg injected at very high doses have a therapeutic effect in several 
auto-immune and inflammatory diseases such as immune thrombocytopenic purpura 
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(ITP) and rheumatoid arthritis (RA). Kaneko et al. demonstrated that IgGs bearing 
sialylated Fc-glycans have anti-inflammatory properties in a RA murine model [17]. The 
inhibitory Fcγ-receptor FcγRIIb as well as Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN) receptor were shown to be involved [18-
21], but the exact mechanism has not been elucidated. In parallel, Van de Geijn et al. 
reported that the increased levels of IgG1 galactosylation and sialylation during 
pregnancy may be responsible for the improved condition of RA-affected pregnant 
women [22]. 
IVIg are IgGs pooled and purified from sera of 3000 to 10000 donors. The sialylated fraction 
represents around 10% of the total IgGs present in the pool. To be therapeutically effective, 
IVIg used as an anti-inflammatory drug require repeated injections of very high doses (1-
3g/kg). As IVIg are successfully used in an increasing number of applications, a lack of 
donors is expected in the near future [23, 24]. To increase the therapeutic efficacy of anti-
inflammatory IgGs and avoid IVIg shortage, one strategy may reside in the production of 
recombinant sialylated IgGs [25]. 
4. Production of sialylated recombinant antibody 
The CHO cell line is the most widely accepted production cell line in the industry for 
therapeutic manufacturing, including monoclonal antibodies. CHO cells have proven to be a 
safe expression system and provide high production yields. IgG and Fc fragment produced 
in CHO cells exhibit a very low level of sialylation (<2%). However, it was shown that a 
single mutation in the CH2 domain, the replacement of Phe243 by an alanine, enhances the 
sialylation level of an IgG3 [26]. CHO glycosylation machinery is very similar to that found 
in human cells but with two major differences: they lack a functional N-
acetylglucosaminyltransferase-III (GnTIII) for the addition of bisecting-GlcNAc and, more 
importantly, they lack the alpha-2,6-sialyltransferase-I activity (ST6Gal-I or SIAT1) 
responsible for the addition of sialic acids on galactose residues with α2,6 an linkage [27]. 
The expression of a recombinant ST6Gal-I is therefore necessary to achieve the production of 
α2,6 sialylated IgGs in CHO cells. 
Large-scale transfection strategies allow for the rapid expression of recombinant 
glycoproteins. The HEK293 cell line is easily transfectable with a variety of gene transfer 
reagents, and is probably the most utilized cell line for large-scale transient gene expression 
[28, 29]. More recently, approaches using CHO cells have also been developed that provide 
tens to hundreds of milligrams of protein per litre [30]. In order to generate high titres of 
antibodies with enhanced α2,6-sialylation, we optimized the conditions for the transient co-
expression of human ST6Gal-I together with IgG light and heavy chains in CHO and HEK293 
cells. Our model antibody, Herceptin (or trastuzumab, herein abbreviated TZM), is a 
humanized mouse IgG1 used in the treatment of HER2-positive breast cancer. TZM has no 
glycosylation site on the Fab fragment but only the N297 sites on each CH2 domains of the Fc. 
We compared sialylation of the wild-type antibody to the F246A mutant (TZMm), which is 
equivalent to the IgG3 F243A mutant described previously [26]. 
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5. Materials and methods 
Mammalian cell culture 
The human embryonic kidney 293-6E cell line stably expressing truncated Epstein-Barr 
virus Nuclear Antigen-1 (EBNA1) and the Chinese hamster ovary cell line also expressing a 
truncated EBNA1 protein (clone 3E7, or CHO-3E7) were grown in suspension culture in 
serum-free F17 medium (Invitrogen, Carlsbad, CA) supplemented with 0.1% Pluronic-F68, 
25 µg/mL geneticin G418 (for 293-6E cells only) and 4 mM glutamine [31]. Cultures were 
maintained between 0.1 and 2.0 x 106 cells/mL in 125 mL ventilated Erlenmeyer flasks 
shaken at 120 rpm in a humidified incubator at 37°C with 5% CO2. 
Plasmids 
The light (LC), heavy (HC), and F246A mutated heavy (HCF246A) chains were cloned 
between the EcoRI and BamHI sites of the pTT5 vector [32, 33]. The human ST6Gal1 gene 
was cloned between the HindIII and BamHI sites of the pYD7 vector [34]. Green fluorescent 
protein (GFP) cloned into the pTT vector was used as a reporter gene to evaluate 
transfection efficiency [35]. Plasmids were amplified in Escherichia coli (DH5α) grown 
overnight in CircleGrow medium (MP Biomedical, Solon, OH) supplemented with 
100ug/mL ampicillin and purified using MAXIprep or QIAprep spin Miniprep columns 
(Qiagen, Mississauga, ON). 
Transfection 
Linear 25 kDa polyethylenimine
1
 (LPEI), and linear deacylated polyethylenimine (PEI max) 
were obtained from Polysciences (Warrington, PA). Stock solutions (1 mg/mL and 3 mg/mL 
for LPEI and PEImax respectively) were prepared in ultrapure water, sterilized by filtration 
(0.2 µm), aliquoted and stored at 4°C. Cells were diluted 2 days before transfection in fresh 
medium at 0.5 and 0.2 x 106 cells/mL for 293-6E and CHO 3E7 cells respectively. Cells were 
transfected at densities between 1.5 and 2 x 106 cells/mL. DNA and PEI were separately 
diluted in complete serum-free F17 medium in sterile tubes. Transfection reagents volume 
was 10% of the final culture volume. The final DNA concentration was 1 µg per mL of 293-
6E culture, and 1.5 µg per mL of 3E7 culture. PEI was used at the final concentration of 3 µg 
per mL in 293-6E culture and 7 µg per mL in 3E7 culture. Plasmid DNA mix was directly 
added to the cells and the suspension was allowed to incubate under agitation for 5 min at 
37°C before the addition of PEI according to the direct transfection protocol [46]. Cells were 
fed 24 hours post-transfection (hpt) with TN1 peptone to a final concentration of 0.5% (w/w) 
to enhance productivity [28]. Transfection efficiency was assessed 48 hpt by determining the 
percentage of GFP positive cells and GFP fluorescence intensity by flow cytometry 
with a BD LSRII cytometer (BD Biosciences, Mississauga, ON). Only viable single cells were 
taken in account. Cell density and viability were determined using the Cedex Innovatis 
                                                                 
1 "Use of PEI for transfection may be covered  by  existing  intellectual  property  rights,  including  US  Patent  
6,013,240, European Patent 0,770,140, and foreign equivalents for which further information may be obtained by 
contacting licensing@polyplus-transfection.com” 
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automated cell counter Cedex Analyzer (Roche, Laval, QC) based on the trypan blue 
exclusion method. 
Purification of Mabs from cell culture supernatants 
Cell cultures were centrifuged 20 min at 3000g. The supernatant was collected and loaded 
on a 4mL MabSelect SuRe column (GE Healthcare, Mississauga, ON) equilibrated in PBS. 
The column was washed with PBS and Mabs were eluted with 100mM citrate buffer pH 3.0. 
The fractions containing Mabs were pooled and the citrate buffer was exchanged against 
water on Econo-Pac® 10DG columns (Bio-Rad, Mississauga, ON). Purified Mabs were 
sterilized by passing through 0.2 µm filters, aliquoted, and stored at -80°C. 
Quantification of Mabs 
Concentration of TZM and TZMm in culture supernatants were determined by protein-A 
HPLC using a 800 µL POROS® 20 micron Protein A ID Cartridge (Applied BioSystems, 
Foster City, CA) according to the manufacturer’s recommendations. The antibody present in 
the culture medium was also visualized following reducing and non-reducing SDS-PAGE 
stained by Bio-Safe Coomassie Stain (Bio-Rad, Mississauga, ON). Purified Mab were 
quantified by absorbance at 280 nm using a Nanodrop™ spectrophotometer 
(ThermoScientific). 
Lectin-Blot for α2,6-sialylation evaluation 
α2,6 sialylation was assessed by lectin-blotting on denatured and reduced antibody to 
separate HC from LC. After protein transfer, nitrocellulose membrane was incubated 3 
hours with biotinylated Sambucus Nigra (SNA) lectin (Vector Laboratories, Burlingame, 
CA), then incubated with Streptavidin-Peroxidase Polymer (Sigma, Saint Louis, MO) for one 
hour. Signal was revealed with BM Chemiluminescence Blotting Substrate (POD) (Roche 
Applied Science, Indianapolis, IN). 
Isoelectric focusing (IEF) 
Purified Mabs were analysed on PhastGel™ 3-10, run on the PhastSystem™ (Amersham 
Biosciences, Baie d’Urfe, QC) according to the manufacturer’s recommendations. Gels were 
fixed in trichloroacetic acid (TCA) 5% in water (w/w) and stained with Coomassie blue 
0.02%.  
Enzymatic removal of sialic acids 
α2,3 linked sialic acids were enzymatically removed from the purified antibody by 
Streptococcus pneumoniae Glyko Sialidase S (PROzyme, Hayward, CA) after one hour 
incubation at 37°C. Total sialylation (α2,6 and α2,3 sialic acids) was removed after 
incubation overnight at 37°C with Arthrobacter ureafaciens Neuraminidase (MP Biomedicals, 
Solon, OH). 
Mass spectrometry 
Peptide-N-glycosidase F (PNGaseF) was purchased from Roche (Mannheim, Germany). 
Phenylhydrazine (PHN), phenylhydrazine hydrochloride (PHN.HCl), iodomethane (MeI), 
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dimethylsulfoxide (DMSO), 2,5-dihydroxybenzoic acid (DHB) and 2-aza-2-thiothymine 
(ATT) were obtained from Sigma (St. Louis, MO, USA). Carbon and STRATA-X-C cartridges 
were purchased from Phenomenex (Torrance, CA).  Solid sodium hydroxide (NaOH) and 
HPLC-grade solvents (acetonitrile (ACN), chloroform, methanol) were obtained from Fisher 
Scientific (Fair Lawn, NJ). HPLC-grade water was obtained with a Milli-Q® plus TOC water 
purification system (Millipore, Bedford, MA).  
Release of N-linked oligosaccharides from samples and MALDI-MS analysis 
To the sample solution (100 µL; 50µg glycoprotein) 2 µL of PNGaseF were added and 
incubated at 37°C for 5-18 h. One µL of digested mixture was loaded onto a spot with 
freshly prepared matrix solution (0.8 µL; 5 mg of ATT and 2.5 mg of PHN.HCl dissolved in 
350 µL 50% ACN in water) predeposited on the surface of a MALDI target. When the 
mixture was partially dried, 0.4 µL of PHN-labelling solution (phenylhydrazine:deionized 
water:ACN/1:4:1) was added to the spot with sample-matrix and left to air air-dry. The 
samples were analysed by MALDI-TOF/TOF-MS (UltrafleXtremeTM, Bruker) in both 
positive and negative ion modes. For the structural analysis individual parent ions were 
manually selected. MS/MS spectra of oligosaccharides were interpreted manually. The 
structures of N-glycans were derived on the basis of fragmentation patterns which were 
produced under MS/MS conditions for single precursor ions. For a discrimination of 
isomeric structures, general rules described in previous study have been applied [36].  
To verify glycan profiles obtained by PHN-target derivatization immediately after PNGaseF 
treatment, all digested samples were also purified on STRATA-XC cartridges combined 
with carbon cartridges. After washing carbon cartridge with 4x1000µL of deionized water, 
glycans were eluted with 40% ACN (1000µL). After total evaporation the glycans were 
labelled with PHN as described above or permethylated according to the procedure 
described by Ciucanu and Kerek [47]. Briefly, dried fractions containing oligosaccharides 
were dissolved in DMSO (40 µL), to which NaOH (2 mg) and methyl iodide (8 µL) were 
added. The mixture was vortexed vigorously (30 min) at room temperature. Then, the 
reaction was stopped by adding ice-cold water (500 µL) followed by chloroform (200 µL). 
After mixing and centrifugation, the upper aqueous layer was discarded and the chloroform 
portion was again washed with distilled water (4 X 500 µL each). Chloroform was 
evaporated and the sample was reconstituted in 70% aqueous methanol (5 µL).One µL of 
permethylated sample solution was spotted into DHB matrix and analysed by MS. 
Intact mass analysis of Mabs 
The antibody isolates were analysed by Trap-LC-MS using an Agilent 1100 series HPLC 
system coupled to a Q-TOF2 hybrid quadrupole time-of-flight mass spectrometer (Waters) 
equipped with an electrospray interface.  Approximately 3 µg of antibody was injected onto 
a Protein MicroTrap (Michrom BioResources/Dionex).  The trap was washed with deionized 
water (~500 µL) to remove buffers prior to being switched on-line with the LC-MS system.  
The antibody was eluted using a linear gradient from 1% to 85% solvent B in 27min (solvent 
A: 0.1% formic acid, solvent B: 0.1% formic acid in acetonitrile, flow rate: 0.45mL/min). The 
mobile phase was split before the trap to 50µL/min.  The electrospray voltage was 4200V 
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and cone voltage was 80V.  The Q-TOF2 mass spectrometer was calibrated for high mass 
range using cesium iodide.  Mass spectra were acquired every 2 seconds during the analyses 
over the full mass range (m/z 50-4000).  The mass spectra acquired across the protein peak 
were combined and smoothed (smooth window: ± 3, number of smooths: 8, smoothing 
method: Savitsky-Golay) and deconvoluted using the MassLynx MaxEnt 1 software from 
Waters: spectral window: m/z 2500-3200, molecular weight range: 140,000-160,000 Da, 
resolution: 1.00Da/channel, damage model: simulated isotope pattern spectrometer blur 
width of 0.500Da, minimum intensity ratios: 60% left, 60% right, number of iterations: 15).  
Peaks in the molecular weight profile were integrated using the MassLynx software. 
6. Results 
6.1. Transfection conditions optimization 
DNA ratio parameters 
Transfection efficacy relies on a variety of parameters that are, amongst others, cell line- 
protein- and plasmid-dependent. We expressed our model Mab together with the human 
α2,6 sialyltransferase (ST6Gal-I) by performing co-transfection of the Mab heavy chain (HC), 
light chain (LC) and ST6Gal-I expressing plasmids. The optimal proportions of each plasmid 
were determined to ensure 1) the proper assembly of the Mab, 2) high sialylation levels and 
3) high Mab yields. The LC:HC and (LC:HC):ST6Gal-I ratios were then assessed in CHO and 
293 cells in suspension in 6-well plates, after 5 days at 37°C. The supernatants were collected 
and analysed by protein-A HPLC (Fig. 2A) and by SDS-PAGE followed by Coomassie 
staining (Fig. 2B) to evaluate the expression yield and proper assembly of antibodies. 
Sialylation was assessed by SNA-blotting (Fig. 2C). For TZMm, a slight excess of LC plasmid 
(LC:HC of 6:4) provided a better expression yield in both cell lines. For wild-type TZM, this 
ratio was of 5:5 in 293 and 6:4 in CHO cells. A ratio 6:4 was chosen for the expression of 
TZM and TZMm in both cell lines. As for sialylation, 20% of ST6Gal-I plasmid was found to 
allow maximum signal in SNA blots without significantly affecting TZMm expression yields 
in both cell lines. It is worth noticing that the sialylation of the wild-type antibody remained 
very low for all ST6Gal-I plasmid ratios, suggesting the inability of the enzyme to sialylate 
TZM. Mab yields were increased in 293 cells with the incorporation of 30% of non-coding 
DNA (salmon sperm DNA) in the final DNA mix, while this was unnecessary in CHO cells 
(data not shown). 
Transfection protocol 
The usual polyethylenimine (PEI) mediated transfection protocol involves the formation of 
DNA-PEI complexes (polyplexes) prior to their addition to the cells. Another approach, the 
direct transfection, consists of the successive addition of DNA and PEI to the cell 
suspension, and was validated with 293 cells to facilitate large-scale transfection handling 
[46, 48]. This strategy was adapted here for CHO cells. 1.5 µg of DNA and 7 µg of PEI per 
mL of culture allowed the expression of amounts of IgGs equal to the classic indirect 
protocol (Fig. 3). Transfection parameters for CHO and 293 cells are summarized in Table 2. 
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Figure 2. Optimization of LC:HC and ST6Gal-I ratio. Panel A – Mabs were quantified by protein-A 
HPLC in 293 and CHO supernatants 5 days post-transfection. Different LC:HC and LC:HC F246A DNA 
ratios were tested for proper expression of TZM and TZMm respectively. Panel B – The supernatants 
were loaded on SDS-PAGE (non-reducing) and stained with Coomassie blue. LC:HC ratios are: Lane 1: 
9:1; Lane 2: 8:2; Lane 3: 7:3; Lane 4: 6:4; Lane 5: 5:5; Lane 6: 4:6. Panel C – Determination of the optimal 
ST6Gal-I ratio. Supernatants from cells transfected with TZMm HC and LC and various ST6Gal-I ratios 
were harvested 5 days post-transfection, separated by SDS-PAGE (reducing conditions) and transferred 
on nitrocellulose membrane for the determination of the sialylation level by blotting with SNA-HRP. 
Nitrocellulose membrane was stained with Ponceau red for protein load control, or incubated with 
SNA-HRP. Proportion of ST6Gal-I plasmid in transfection mixture was: Lane 1: 0%; Lane 2: 10%; Lane 3: 
20%; Lane 4: 30%; Lane 5: 40%; Lane 6: 50%. 
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Figure 3. Determination of the optimal transfection parameters. Final concentrations of DNA and PEI 
per mL of culture for direct transfection of CHO cells were determined for TZM. Closed squares 
represent the TZM titres obtained using the traditional indirect protocol, i.e. with DNA-PEI 
complexation prior to the addition to the cell culture (PEI 5µg/mL). Open symbols represent the results 
for 3 different PEI concentrations with direct protocol: open circle: 7 µg/mL; open triangle: 6 µg/mL; 
open diamond 5 µg/mL. Results represent the average of three independent experiments ± SD. 
 
 293 CHO 
LC:HC 6:4 6:4 
(LC:HC):ST6Gal-I (80):20 (80):20 
((LC:HC):ST6Gal-I):ssDNA (70):30 (100):0 
DNA:PEI for Direct protocol 1:3 (LPEI) 1.5:7 (PEI max) 
Table 2. Optimal DNA and PEI ratios determined for the expression of TZM and TZM F246A mutant 
(TZMm) in 293-6E and CHO cells using the direct transfection protocol.   
6.2. Mab expression and sialylation kinetics 
Sialylation is likely to be limited after a certain time in batch culture due to a combination of 
adverse factors such as, but not limited to, ammonia accumulation [37, 38], ST6Gal-I 
plasmid loss upon successive cell division and sialidases release in medium [39]. As Mab 
titre increases over time in the culture medium, the harvest time point selected must provide 
an acceptable compromise between high Mab yield and high sialylation. In this study, we 
gave priority to sialylation over Mab expression yield. 
Sialylation kinetics was studied on the mutant antibody as sialylation of TZM was barely 
detectable. TZMm co-expression with ST6Gal-I was carried out for 7 days in 293 and CHO 
cells, until viability dropped to approximately 60% (Fig. 4A). A fraction of each culture was 
harvested daily from day 3 to day 7 and purified by protein-A affinity chromatography. 
Sialylation level of the purified TZMm fractions were assessed by SNA-blotting and IEF 
analyses. 
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Figure 4. Production kinetic of TZMm in 293 and CHO cells. Panel A - Cell growth and viability for 
TZMm co-expression with ST6Gal-I.  Cells were transfected at t=0h and fed at 24h post-transfection 
with TN1 peptone (0.5% w/v final). Open and closed circles: viability and viable cell density in 293 cell 
cultures. Open and closed triangles: viability and viable cell density in CHO cell cultures. Panel B - 
TZMm yield over time as determined by protein-A HPLC quantification of each fraction. Closed circles: 
titres in 293 cells; closed triangles: titres in CHO cells. 
In 293 cells, SNA-blot showed a maximum α2,6-sialylation on day 3, which then decreased 
over time (Fig. 5A). In CHO cells, no significant loss of intensity was observed, suggesting 
that α2,6-sialylation of the heavy chain was more stable over time. These patterns were 
supported by IEF analyses. Due to the negative charge of sialic acid, mono, di, tri and tetra-
sialylated Mabs are expected to have lower pI than asialylated glycoforms. Even though 
these variations in pI are small, they could be easily distinguished on IEF gels. The upper 
band intensity showed a higher amount of asialylated glycoforms in 293 than in CHO as 
seen on the blot (Fig. 5B). The decline in the sialylation level was less obvious by IEF vs 
SNA-blot analysis for the 293 cells, which could be explained by a change in the α2,3 / α2,6 
sialylation ratio over time. For CHO cells, the IEF profiles mirrored the SNA-blot results as 
there was no significant band intensity variation among the samples from day 3 to day 7. 
TZM and TZMm treated overnight with α2,3-6 neuraminidase (Arthrobacter ureafaciens) at 
37°C exhibited the same pattern than aglycosylated TZM mutant N297A (Fig. 5C), 
confirming that the lower bands correspond to sialylated states of the Mabs. 
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Figure 5. Sialylation kinetic of TZMm in 293 and CHO cells. Panel A –TZMm was co-expressed with 
ST6Gal-I, harvested from day 3 to day 7 and purified by protein-A chromatography. 300ng were 
resolved by SDS-PAGE (reducing condition), transferred to nitrocellulose membrane and probed with 
SNA-HRP. Only the heavy chain is shown. The membrane was stained with Ponceau red to monitor 
protein loads. Panel B – IEF profiles of purified TZMm co-expressed with ST6Gal-I and harvested 
between day 3 and 7 post-transfection. Mrk: IEF calibration markers. Panel C – IEF profiles of purified 
TZMm from 293 and CHO cells digested or not with A. ureafaciens neuraminidase and of aglycosylated 
TZM (N297A mutant produced in 293 cells). 
6.3. Impact of ST6Gal-I expression and F246A mutation on sialylation patterns 
Impact of ST6Gal-I overexpression and F246A mutation on TZM sialylation 
To evaluate the impact of ST6Gal-I expression on overall sialylation levels of TZM and 
TZMm, purified Mabs were submitted to SNA blotting and IEF analyses (Figure 6). While 
SNA blot (panel A) shows a significant increase in α2,6-sialylation levels of TZMm, no 
increase in sialylation of the wild-type antibody could be observed in 293 cells while only a 
faint band could be seen in CHO cells. In 293 cells, only a marginal signal with SNA lectin 
could be seen when TZMm was expressed alone, suggesting that endogenous levels of 
ST6Gal-I activity are low in this cell line. The main consequence of ST6Gal-I co-expression 
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was the significant preference for α2,6-sialylation over α2,3-sialylation of TZMm in CHO 
cells. While all of the acidic TZMm species observed when the Mab was expressed alone 
disappeared after treatment with Sialidase S (an α2,3-specific neuraminidase), these acidic 
species became resistant to Sialidase S when ST6Gal-I was co-expressed. This suggests that 
sialylation of TZMm in the presence of ST6Gal-I was mostly due to the preferential addition 
of α2,6- over α2,3-sialic acid residues. 
 
Figure 6. Impact of ST6Gal-I expression and F246A mutation on TZM sialylation. Transfected CHO and 
293 cultures (with or without ST6Gal-I) were harvested on day 3 and day 4, respectively and Mabs were 
purified by protein A chromatography. Panel A – Mabs (300ng per lane) were resolved by SDS-PAGE 
(reducing conditions) and submitted to SNA-blotting (only the heavy chains are shown). Panel B – IEF 
analyses of Mabs from 293 and CHO cells treated or not with Sialidase S (α2,3-neuraminidase). 
Glycan analysis by MALDI-MS spectrometry 
After PNGaseF digestion of the purified Mabs, oligosaccharide detection was firstly achieved 
by MALDI-MS directly after non-reductive on-target derivatization with phenylhydrazine 
(PHN) without using any purification procedure. Despite a presence of side products and salts 
coming from original buffer, which generally have a tendency to suppress signal peaks 
corresponding to glycans, all samples provided good evidence for the presence of N-glycans. 
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These N-glycans were known to be located on the Fc fragment as Asparagine 297 is the only 
glycosylation site in our model antibody. The profile differences between the samples in CHO 
and 293 were consistent with what was observed by SNA-blot and IEF. The dominant 
oligosaccharides derived from all Mab samples were observed in positive mode in PHN-
derivatized samples at m/z 1575, 1737 and were consistent with biantennary core-fucosylated 
structures with zero and one galactose. Glycan having both antennae occupied with galactoses 
(m/z 1899) was observed with higher intensity only in TZMm samples without ST6Gal-I. 
The spectra recorded in the negative mode from TZM samples co-expressed with ST6Gal-I 
and derivatized with PHN, provided evidence for the presence of small amount of 
monosialylated glycans structure - NeuAcGal1-2GlcNAc2Man3GlcNAc2Fuc (Figure 7A & 7E).  
Sialylated glycans were clearly detected at higher levels in TZMm samples. TZMm samples 
co-expressed with ST6Gal-I in both cell lines (Fig. 7C & 7G) indicated higher sialylation 
degree than that obtained under control conditions (Fig. 7D & 7H).  
 
Figure 7. Glycan analysis by MALDI-MS in negative mode. Negative MALDI-MS spectra of N-Glycans 
obtained after PNGase F digestion and on-target derivatization with PHN (+90 Da) of MAbs from 293 
cells (panels A to D) and CHO cells (panels E to H). Monosialylated glycans (m/z at 2005 and 2167) are 
detected as [M-H]- ions. 
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The high level of sialylated glycans was even better observed in the fractions obtained after 
purification prior to derivatization, as shown in Figure 8 which represents MS spectra 
recorded from TZMm samples produced in 293 cells. Interestingly, this analysis revealed 
traces of triantennary glycans in TZMm that cannot naturally occur in wild-type IgG1, 
supporting the vision of an open Fc conformation presenting reduced space constraint to the 
glycosyltransferases. 
 
 
 
 
Figure 8. Glycan analysis by MALDI-MS in positive mode. Positive MALDI-MS spectra of N-glycans 
recorded after glycans purification and permethylation from PNGase digested TZMm produced in 293 
cells. All glycans are as [M+Na]+. 
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Intact mass analysis of antibodies by LC-ESI-MS using a Q-TOF2 spectrometer 
The intact mass analysis approach allowed us to see the outcome of the pairing of the 
glycans on the overall glycosylation of the antibodies, and to distinguish with a high 
resolution between galactosylated and sialylated Mabs glycoforms. The prevalence of 
agalactosylated and monogalactosylated glycoforms in TZM+/-ST6 samples in both cell lines 
was consistent with the glycan analysis by MALDI-MS (Fig. 9A). No trace of sialylated  
 
 
 
 
 
 
Figure 9. Intact antibody analysis of Mabs by by LC-ESI-MS. Purified Mabs produced in CHO cells 
were analyzed by LC-ESI-MS on a Q-TOF2 spectrometer as described in Materials and Methods. Panel 
A: TZM+ST6; panel B: TZMm+ST6. 
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antibodies was detected. The close resemblance of the profiles of TZM produced in the 
presence or absence of ST6Gal-I confirmed the poor sialylation efficacy of the wild-type 
antibody. In contrast, the association of the Fc F246A mutation with the expression of 
ST6Gal-I in CHO cells resulted in a massive conversion of the neutral Mabs into a variety of 
mono-, di-, tri- and tetrasialylated antibodies, where the tetrasialylated version was 
predominant (Fig. 9B). The combination of the two approaches in 293 cells, as well as the Fc 
mutation alone in both cell lines provided intermediate results (not shown). 
7. Discussion 
IVIg are successfully used for the treatment of an increasing number of autoimmune and 
inflammatory disorders. Their efficacy results from several distinct mechanisms working 
together in a complex fashion that is not yet understood. Anti-inflammatory mechanisms of 
IVIg may involve distinct pathways via FcRn or FcyRIIb receptors. Kaneko et al. highlighted 
the implication of the Fc α2,6-sialylated fraction of IVIg in a murine model of rheumatoid 
arthritis [17]. The production of sialylated IgGs with potentially enhanced specificity and 
efficacy may provide a safe alternative to IVIg and could also compensate for possible IVIg 
shortage. The ability to generate highly sialylated IgGs could also help in gaining a better 
understanding of their mechanism of action. 
Several approaches are used to enhance the sialylation level of recombinant proteins 
produced in mammalian cell cultures, such as cell line engineering, bioprocess control, post-
production enrichment (such as lectin-affinity purification) and in vitro glycan remodelling 
[27, 40]. In the field of mammalian cell engineering, a variety of approaches were developed. 
Antisense RNA and short interfering RNA were used in CHO cell lines to knock-down 
genes encoding for sialidases, leading to a significant increase in total amount of sialic acid 
in recombinant proteins [39, 41]. Smaller but still significant improvement was achieved by 
the overexpression of CMP-sialic acid transporter, either alone [42] or in combination with 
CMP-sialic acid substrate [43]. Among the variety of approaches, the expression of the 
ST6Gal-I gene remains the only way to introduce α2,6-linked sialic acids on proteins in CHO 
cells. 
The results obtained in this study were very similar to those of Jassal et al. on a monoclonal 
antibody of the IgG3 subtype [26]. The replacement of phenylalanine 246, equivalent to F243 
in IgG3, by an alanine residue was necessary to reach significant sialylation levels, and the 
impact of this mutation was much stronger than that of human ST6Gal-I over-expression in 
both 293 and CHO cell lines. This confirms that IgG1 Fc structure strongly limits glycan 
accessibility to the sialyltransferases. The intact mass analysis profile of the mutant co-
expressed with ST6Gal-I in CHO was dominated by the fully sialylated Mab, followed by 
tri-, di- and monosialylated forms.  
Replacing the phenylalanine with an alanine residue decreases the hydrophobic 
environment that maintains the glycan buried in the Fc. Multiple mutation strategies are a 
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powerful mean to promote glycosylation enhancement and Fc affinity for FcγRs. 
Computational modeling allows the design of antibodies with amino acid mutations that are 
not even exposed on the surface of the glycan pocket. However, the accumulation of 
mutations in a therapeutic Mab can have unpredictable side effects [44]. In the first place, 
mutation may compromise the affinity of the Mab for potential receptors involved in the 
anti-inflammatory mechanism. Also, non-natural Mab glycan structures (like sialylated tri-
antennary glycans) may reduce their biological activity or even render them immunogenic. 
In a recent study, the CHO ST6Gal-I gene, present but not expressed, was cloned and stably 
expressed in these cells [45]. As a result, 70% of the glycans of a stably expressed IgG1 and 
released by PNGaseF were sialylated. This striking result was thought to be conferred by a 
higher propensity of the CHO ST6Gal-I gene product for Fc glycan compared to its human 
or rat homologues, possibly due to some mutations in the substrate binding region. The use 
of this particular CHO ST6Gal-I gene may provide an interesting alternative strategy 
independent any IgG mutations to enhance sialylation of Mabs. 
The production of highly sialylated IgGs in large quantities will probably be achieved by the 
simultaneous use of cell line engineering, Fc engineering, bioprocess control and 
downstream processing. Alternatively, optimizing in vitro glycan remodeling using ST6Gal-I 
and CMP-sialic acid may represent another cost-effective way to produce industrial 
amounts of sialylated IgGs [12]. From the perspective of obtaining a safe and reliable 
alternative to IVIg for anti-inflammatory applications, the production of sialylated 
recombinant Fc could be an attractive approach. However, developing these molecules as 
therapeutics awaits a better understanding of their mode of action. 
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